Compare ROP & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROP | ILMN |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1B | 32.3B |
| IPO Year | 2002 | 2000 |
| Metric | ROP | ILMN |
|---|---|---|
| Price | $385.10 | $224.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 17 |
| Target Price | ★ $492.60 | $124.24 |
| AVG Volume (30 Days) | 583.1K | ★ 1.7M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | ★ 16.35 | 2.22 |
| Revenue | ★ $7,902,500,000.00 | $4,343,000,000.00 |
| Revenue This Year | $8.80 | $6.47 |
| Revenue Next Year | $6.73 | $5.58 |
| P/E Ratio | ★ $23.76 | $93.00 |
| Revenue Growth | ★ 12.26 | N/A |
| 52 Week Low | $305.96 | $88.00 |
| 52 Week High | $521.24 | $231.81 |
| Indicator | ROP | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 48.37 |
| Support Level | $343.25 | $116.43 |
| Resistance Level | $408.02 | $207.00 |
| Average True Range (ATR) | 8.65 | 7.41 |
| MACD | -4.27 | -2.32 |
| Stochastic Oscillator | 40.95 | 14.80 |
Roper Technologies is a holding company focused on acquiring, managing, and developing niche market-leading technology businesses. The company operates a decentralized business model whereby each portfolio company operates independently from the others. Roper positions itself as a free cash flow compounder, whereby excess free cash flow generated by its portfolio businesses is repatriated to the parent company, which is then utilized to acquire additional businesses. Presently, the company operates 30 distinct businesses with over three-fourths of the revenue coming from software products and over two-thirds of revenue coming from recurring and reoccurring sources.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.